Masimo (MASI)
(Delayed Data from NSDQ)
$127.18 USD
+0.18 (0.14%)
Updated May 28, 2024 04:00 PM ET
After-Market: $128.46 +1.28 (1.01%) 7:58 PM ET
2-Buy of 5 2
C Value C Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$127.18 USD
+0.18 (0.14%)
Updated May 28, 2024 04:00 PM ET
After-Market: $128.46 +1.28 (1.01%) 7:58 PM ET
2-Buy of 5 2
C Value C Growth C Momentum C VGM
Zacks News
Stryker's (SYK) Q Guidance System Receives FDA Approval
by Zacks Equity Research
Stryker's (SYK) Q Guidance System is expected to be a procedural ecosystem for surgeons during image-guided surgery following the receipt of the FDA approval.
Thermo Fisher (TMO) North America Sales Grow, Margin Woe Stays
by Zacks Equity Research
Thermo Fisher (TMO) witnesses core business strength across segments, end markets, and geographies.
Is Masimo (MASI) a Solid Growth Stock? 3 Reasons to Think " Yes "
by Zacks Equity Research
Masimo (MASI) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Reasons to Retain Integer Holdings (ITGR) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Integer Holdings (ITGR) owing to its improving non-medical sales and solid foothold in the broader MedTech space.
Here's Why Investors Should Retain Illumina (ILMN) Stock Now
by Zacks Equity Research
Investors are optimistic about Illumina's (ILMN) better-than-expected results and revenue contributions from the GRAIL business.
Here's Why You Should Retain PerkinElmer (PKI) Stock Now
by Zacks Equity Research
PerkinElmer (PKI) continues to gain momentum from a solid product portfolio and healthy margins. However, forex woes linger.
Tandem Diabetes (TNDM) Pump Shipment Recovers, Price Issue Ails
by Zacks Equity Research
Tandem Diabetes (TNDM) witnesses strong customer retention, driven by the impressive positive response from the Control-IQ technology.
Integra (IART) Gains From Innovation Amid Cost Constraints
by Zacks Equity Research
Integra's (IART) international sales in CSS grow led by the strong performance of CereLink in Europe and growth in Asia.
CVS Health (CVS) to Improve Primary Care With New Offering
by Zacks Equity Research
CVS Health (CVS) debuts the new CVS Health Virtual Primary Care solution to allow consumers to obtain care whenever necessary.
NextGen Healthcare (NXGN) Unveils Health Data Hub Insights
by Zacks Equity Research
NextGen Healthcare's (NXGN) newly launched tool can help healthcare providers to receive a complete picture of the community and patient health.
Here's Why You Should Retain Merit Medical (MMSI) Stock Now
by Zacks Equity Research
Investors continue to be optimistic about Merit Medical (MMSI) due to its strong product portfolio.
Walgreens Boots (WBA) Omnichannel Aids Growth Amid Cost Woes
by Zacks Equity Research
The continued acceleration of Walgreens' (WBA) omnichannel offerings and a significant rise in MyWalgreens membership are notable upsides in recent times.
Medtronic's (MDT) Q4 Earnings and Revenues Lag Estimates
by Zacks Equity Research
On a positive note, Medtronic (MDT) registers organic growth in the Cardiovascular and Neuroscience segments.
Change Healthcare (CHNG) Q4 Earnings Miss Estimates, Revenues Top
by Zacks Equity Research
Change Healthcare's (CHNG) fiscal fourth-quarter results benefit from solid performance across Software and Analytics, Network Solutions and Technology-Enabled segments.
Cooper Companies (COO) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
Cooper Companies' (COO) fiscal second-quarter results are likely to reflect segmental strength.
Illumina (ILMN) to Offer Companion Diagnostic for VITRAKVI
by Zacks Equity Research
Illumina's (ILMN) first companion diagnostic claim for TSO Comprehensive (EU) will help identify cancer patients with NTRK gene fusions for a genomically matched treatment.
Here's Why You Must Add Masimo (MASI) Stock to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Masimo (MASI) due to its focus on patient monitoring.
Masimo's (MASI) PVi Favored by New Study for Pediatric Patients
by Zacks Equity Research
Masimo's (MASI) PVi is expected to take better treatment decisions for pediatric patients with signs of obstructive respiratory disease in the EDs.
NextGen Healthcare's (NXGN) Solutions Selected by MHHC
by Zacks Equity Research
NextGen Healthcare's (NXGN) solutions get chosen by MHHC that can help serve the latter's rapidly growing community efficiently.
Veeva Systems (VEEV) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Veeva Systems' (VEEV) fiscal first-quarter results are likely to reflect a solid show by its segments and robust product portfolio.
What's in Store for Canopy Growth (CGC) in Q4 Earnings?
by Zacks Equity Research
Product launches across the CBD product portfolio and robust demand for legal cannabis products are likely to have driven Canopy Growth's (CGC) Q4 top line.
Here's Why You Should Retain Change Healthcare (CHNG) Stock
by Zacks Equity Research
Change Healthcare (CHNG) continues to benefit from strategic deals. However, intense competition remains a woe.
Thermo Fisher (TMO) to Advance Precision Medicine in Qatar
by Zacks Equity Research
Thermo Fisher's (TMO) collaboration with Qatar Genome Program will utilize the power of genomics to enhance the standard of healthcare for the Qatari population.
What's in the Cards for Medtronic (MDT) in Q4 Earnings?
by Zacks Equity Research
Medtronic's (MDT) Cardiovascular business is expected to have gained share in both high and low power devices in Q4.
Can Masimo (MASI) Run Higher on Rising Earnings Estimates?
by Zacks Equity Research
Masimo (MASI) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.